Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PDS 0102

Drug Profile

PDS 0102

Alternative Names: PDS-0102; Versamune®-TARP

Latest Information Update: 22 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PDS Biotechnology Corporation
  • Developer National Cancer Institute (USA); PDS Biotechnology Corporation
  • Class Antineoplastics; Immunotherapies; Peptides
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Breast cancer; Prostate cancer

Most Recent Events

  • 08 Nov 2021 T-cell receptor gamma alternate reading frame protein (TARP) licensed to PDS Biotechnology
  • 17 Jun 2021 PDS Biotechnology plans clinical trials for Acute myeloid leukaemia, Breast cancer and Prostate cancer (SC, Injection) in 2022
  • 01 Jun 2021 PDS 0102 is available for licensing as of 18 May 2021. https://pdsbiotech.com/versamune-platform/partnerships
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top